Additional file 1 of Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity
Creators: name: Ruyssen-Witrand, Adeline
name: Guernec, Gregory
name: Dupont, Julia
name: Lapuyade, Diane
name: Lioté, Frédéric
name: Vittecoq, Olivier
name: Degboé, Yannick
name: Constantin, Arnaud
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Biotechnology
subject: Ecology
subject: FOS: Biological sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: Statistics
subject: FOS: Mathematics
subject: Virology

description: Additional file 1: Supplementary Data S1. Grouping patients according to disease activity state. Supplementary Data S2. Sensitivity analysis. Supplementary Data S3. Multivariate analysis. Supplementary Data. Sensitivity analyses. Supplementary Data S4. When using DAS28-ESR to assess disease activity, comparative analyses showed that patients classified in sustained remission according to DAS28-ESR were females in 70% of cases compared to 88% in the sustained LDA group and 92% in the MDA or HDA groups (p &lt; 0.001) and had shorter disease duration (mean duration in remission group: 6.3 months (SD: 9.0) compared to 8.8 months (SD: 7.5) in the LDA group and 8.4 months (SD: 10.1) in the MDA or HDA groups, p &lt; 0.001) and lower ESR (mean ESR in remission group: 24 (SD: 22) compared to 36 (SD: 28) in the LDA group and 39 (SD: 26) in the MDA or HDA groups, p &lt; 0.001 while CRP levels were comparable across the three groups. Baseline HAQ scores were comparable between patients in sustained remission and LDA and lower than patients in the MDA or HDA groups (mean HAQ in the remission group: 0.86 (SD: 0.61) and 0.88 (SD: 0.64) in the LDA group compared to 1.28 (SD: 0.69) in the MDA or HDA groups, p &lt; 0.001). Patients in the sustained remission group were less exposed to corticosteroids, DMARDs and bDMARDs during the follow-up in the cohort compared to patients in sustained LDA and sustained MDA or HDA (see Table S1). Univariate analyses revealed that patients in sustained remission had lower ten-year mTSS scores and ten-year HAQ scores compared to patients in sustained LDA and patients in sustained MDA or HDA (ten-year mTSS mean in remission group: 47.94 (10.75), compared to 12.18 (16.66) in the LDA group and 22.66 (25.19) in the MDA or HDA groups, p &lt; 0.001, ten-year HAQ in remission group: 0.24 (0.38) compared to 0.58 (0.49) in the LDA group and 1.21 (0.68), p &lt; 0.001). Figure S1. Profile with 95% confidence intervals of each group of patients provided by the optimal lcmm model. The right column provides the composition of each cluster in time by levels of SDAI score. (‘/number’ corresponds to the number of patients by cluster). Supplementary Figure S2. Individual patient trajectory profiles are represented in the graphs below, according to different groups. SDAI trajectories in the whole cohort and in the three groups (group 1= remission, group 2 = LDA, group 3 = MDA or HDA group). Supplementary Figure S3. DAS28 trajectories in the whole cohort and in the three groups (group 1 = remission, group 2 = LDA, group 3 = MDA or HDA group). Supplementary Figure S6. Profiles (with 95% confidence intervals) of mTSS trajectories over ten years using the DAS28-ESR score for disease activity-based groups. Supplementary Figure S8. Results of the modelisation of HAQ evolution over ten years using the DAS28-ESR score for disease activity-based groups. Supplementary Table S1. Example of SDAI. Table S2. Details of the bootstrapped tertiles including validity thresholds (standard method) by disease activity states for SDAI (a) and DAS28 (b). HDA: high disease activity, MDA: moderate disease. Table S3. SDAI group definition sensitivity analysis. Table S4. DAS28-ESR group definition sensitivity analysis. Table S5. Inclusion patient characteristics and treatments taken over time by their DAS28-ESR group during the ten-year follow-up in the ESPOIR cohort. Table S7. Multivariate analysis assessing the ten-year mTSS progression and ten-year HAQ using DAS28-ESR as disease activity score: Wald tests related to the parameter estimates and contrast of the final model. Table S9. Sensitivity analysis by modifying the rules of the definition of the three groups based on SDAI as disease activity score. Comparison of ten-year mTSS progression across the three groups using contrasts from the final model parameters. Table S10. Sensitivity analysis by modifying the rules of the definition of the three groups based on SDAI as disease activity score. Comparison of ten-year HAQ across the three groups using contrasts from the final model parameters. Table S11. Sensitivity analysis by modifying the rules of the definition of the three groups based on DAS28-ESR as the disease activity score. Comparison of ten-year mTSS progression across the three groups using contrasts from the final model parameters. Table S12. Sensitivity analysis by modifying the rules of the definition of the three groups based on DAS28-ESR as the disease activity score. Comparison of ten-year HAQ across the three groups using contrasts from the final model parameters. Table S13. Ten-year serious adverse events according to the three groups of DAS28-ESR: ten-year incidence for 100 patient years. Table S14. Hazard ratios of optimal Cox models to predict ten-year serious adverse events risk with SDAI (a) or DAS28-ESR (b) as rheumatoid arthritis activity scale (N(a) = 252; N(b) = 203).